Targeted protein degraders: Blood–brain barrier permeability and central nervous system exposure

Targeted protein degraders (TPDs), including PROTACs, are emerging as a revolutionary therapeutic strategy for central nervous system (CNS) proteinopathies by leveraging the body's cellular machinery to completely destroy disease-causing misfolded proteins. However, delivering these chemical macromolecules across the blood-brain barrier (BBB) presents a monumental challenge. Standard CNS drugs typically adhere to strict physicochemical parameters, such as low molecular weights and minimal polar surface area. In contrast, TPDs violate these traditional guidelines with molecular weights often exceeding 800 to 1,200 Da, elevated hydrogen bond counts, and heavy efflux transporter liability. Despite these theoretical barriers, several advanced TPDs have successfully demonstrated measurable brain tissue and cerebrospinal fluid exposure in preclinical models.  

To explain this unexpected CNS exposure, researchers are investigating multiple potential mechanisms of BBB passage alongside strategies for structural optimization. Beyond standard transcellular diffusion, TPDs may cross via post-capillary venules, utilize chameleonic conformational shifts to temporarily lower their polar surface area, or interact with specific influx transporters like OATPs. Furthermore, medicinal chemistry approaches—such as rigidifying linkers with piperidine or piperazine groups—are being leveraged to improve metabolic stability and cellular permeability. Researchers also caution that observed brain concentrations in some preclinical studies may actually stem from vehicle- or anesthetic-induced BBB disruption rather than true permeability, emphasizing the need to carefully distinguish between these mechanisms during drug development.  

Ultimately, evaluating the therapeutic potential of CNS-directed TPDs requires looking past traditional pharmacokinetic metrics. Because TPDs operate through an "event-driven" catalytic mechanism rather than occupancy-driven inhibition, target degradation can persist long after the drug has cleared from systemic circulation, resulting in a pronounced PK/PD disconnect. Going forward, overcoming translational hurdles will depend on refining early-stage testing models, mapping brain-enriched E3 ligases, and accounting for the altered proteasomal activity typical of aging or diseased neurons. By unraveling the precise pathways TPDs use to cross the BBB, researchers can better optimize these innovative molecules to treat neurodegenerative diseases at their earliest stages.

Singh, S., Kumar, S., M. Shingatgeri, V., & Srivastava, P. (2025). Targeted protein degraders: Blood–brain barrier permeability and central nervous system exposure. Advanced Neurology, 4, 5140. https://doi.org/10.36922/an.5140